{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T20:10:12Z","timestamp":1723925412677},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgmr.2024.101118","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T08:15:55Z","timestamp":1721031355000},"page":"101118","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative study on incorporation of three recombinant human \u03b1-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs\/tissues of Fabry mice"],"prefix":"10.1016","volume":"40","author":[{"given":"Takahiro","family":"Tsukimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayasu","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2024.101118_bb0005","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Dis."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0010","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0015","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.2147\/DDDT.S207856","article-title":"FOS study group, cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry outcome survey (FOS) analysis","volume":"13","author":"Ramaswami","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0020","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/ckj\/sfaa065","article-title":"Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis","volume":"14","author":"Ortiz","year":"2021","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase a reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International collaborative Fabry disease study group, safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2020.04.003","article-title":"Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: phase I and II\/III clinical studies","volume":"130","author":"Nakamura","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0045","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/biom10060837","article-title":"Rapid clathrin-mediated uptake of recombinant \u03b1-Gal-A to lysosome activates autophagy","volume":"10","author":"Ivanova","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0050","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0055","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1152\/physrev.1995.75.3.591","article-title":"The asialoglycoprotein receptor: relationships between structure, function, and expression","volume":"75","author":"Stockert","year":"1995","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0060","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1083\/jcb.92.3.634","article-title":"Cell surface distribution and intracellular fate of asialoglycoproteins: a morphological and biochemical study of isolated rat hepatocytes and monolayer cultures","volume":"92","author":"Zeitlin","year":"1982","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10545-015-9886-9","article-title":"Mannose receptor-mediated delivery of moss-made \u03b1-galactosidase a efficiently corrects enzyme deficiency in Fabry mice","volume":"39","author":"Shen","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0070","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000526369","article-title":"Megalin-mediated endocytosis in the kidney proximal tubule: relevance to regulation of the renal renin-angiotensin system","volume":"147","author":"Hummelgaard","year":"2023","journal-title":"Nephron"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025065","article-title":"Receptor-mediated endocytosis of \u03b1-galactosidase A in human podocytes in Fabry disease","volume":"6","author":"Prabakaran","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039975","article-title":"Mannose 6-phosphate receptor and sortilin mediated endocytosis of \u03b1-galactosidase A in kidney endothelial cells","volume":"7","author":"Prabakaran","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100243","article-title":"Sorting through the extensive and confusing roles of sortilin in metabolic disease","volume":"63","author":"Mitok","year":"2022","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0095","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ymgme.2018.07.009","article-title":"Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease","volume":"125","author":"Morimoto","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0105","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s10038-007-0210-x","article-title":"Establishment of immortalized Schwann cells from Fabry mice and their low uptake of recombinant alpha-galactosidase","volume":"52","author":"Kawashima","year":"2007","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0110","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0115","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0120","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211060269","article-title":"Genetically modified cell transplantation through macroencapsulated spheroids with scaffolds to treat Fabry disease","volume":"30","author":"Kami","year":"2021","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0125","article-title":"Surface plasmon resonance analysis of complex formation of therapeutic recombinant lysosomal enzymes with domain 9 of human cation-independent mannose 6-phosphate receptor","volume":"25","author":"Kanzaki","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0130","article-title":"Does administration of hydroxychloroquine\/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?","volume":"28","author":"Tsukimura","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0135","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.str.2020.08.002","article-title":"Structure of the human cation-independent mannose 6-phosphate\/IGF2 receptor domains 7-11 uncovers the mannose 6-phosphate binding site of domain 9","volume":"28","author":"Bochel","year":"2020","journal-title":"Structure"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0140","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2174\/092986707782794005","article-title":"Mannose 6-phosphate receptor targeting and its applications in human diseases","volume":"14","author":"Gary-Bobo","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0145","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/bc400365a","article-title":"Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein","volume":"24","author":"Zhou","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/glycob\/cwv001","article-title":"Identification of a fourth mannose 6-phosphate binding site in the cation-independent mannose 6-phosphate receptor","volume":"25","author":"Olson","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgmr.2024.101118_bb0155","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0165","first-page":"424","article-title":"Expression of the insulin-like growth factor-II\/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy","volume":"75","author":"Funk","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2006.11.008","article-title":"Cellular and tissue distribution of intravenously administered agalsidase alfa","volume":"90","author":"Murray","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0190","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cpdd.941","article-title":"Migalastat tissue distribution: extrapolation from mice to humans using pharmacokinetic modeling and comparison with agalsidase beta tissue distribution in mice","volume":"10","author":"Wu","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0195","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ajhg.2009.09.016","article-title":"Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease","volume":"85","author":"Tajima","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0200","first-page":"169","article-title":"Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study, Orphane","volume":"9","author":"Schiffmann","year":"2014","journal-title":"J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0205","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/jimd.12176","article-title":"Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity","volume":"43","author":"Stappers","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0210","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","article-title":"Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgmr.2024.101118_bb0215","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","article-title":"Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages","volume":"33","author":"Kr\u00e4mer","year":"2018","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426924000715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426924000715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T19:35:49Z","timestamp":1723923349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426924000715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":40,"alternative-id":["S2214426924000715"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101118","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative study on incorporation of three recombinant human \u03b1-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs\/tissues of Fabry mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101118"}}